| Literature DB >> 12758173 |
Sandra D Adams1, Wen-Pin Tzeng, Min-Hsin Chen, Teryl K Frey.
Abstract
To investigate whether rubella virus (RUB) undergoes intermolecular RNA-RNA recombination, cells were cotransfected with pairs of in vitro transcripts from genomic cDNA plasmid vectors engineered to contain nonoverlapping deletions: the replicative transcript maintained the 5'-proximal nonstructural (NS) ORF (which contained the replicase, making it RNA replication competent), had a deletion in the 3'-proximal structural protein (SP) ORF, and maintained the 3' end of the genome, including the putative 3' cis-acting elements (CSE), while the nonreplicative transcript consisted of the 3' half of the genome including the SP-ORF and 3' CSE. Cotransfection yielded plaque-forming virus that synthesized the standard genomic and subgenomic RNAs and thus was generated by RNA-RNA recombination. Using transcripts tagged with a 3'-terminal deletion, it was found that recombinants contained the 3' end derived from the replicative strand, indicating a cis-preference for initiation of negative-strand synthesis. In cotransfections in which the replicative transcript lacked the 3' CSE, recombination occurred, albeit at lower efficiency, indicating that initiation in trans from the NS-ORF can occur. The 3' CSE was sufficient as a nonreplicative transcript, showing that it can serve as a promoter for negative-strand RNA synthesis. While deletion mutagenesis showed that the presence of the junction untranslated region (J-UTR) between the ORFs appeared to be necessary on both transcripts for recombination in this region of the genome, analysis with transcripts tagged with restriction sites showed that the J-UTR was not a hot spot for recombination compared to neighboring regions in both ORFs. Sequence analysis of recombinants revealed that both precise (homologous) and imprecise recombination (aberrant, homologous resulting in duplications) occurred; however, imprecise recombination only involved the J-UTR or the 3' end of the NS-ORF and the J-UTR (maintaining the NS-ORF), indicating selection pressure against duplications in other regions of the genome.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12758173 PMCID: PMC7126107 DOI: 10.1016/s0042-6822(03)00064-3
Source DB: PubMed Journal: Virology ISSN: 0042-6822 Impact factor: 3.616
Fig. 1Initial transcript pairs that yielded recombinants. At the top of (A) is a diagram of the RUB genome (ORFs as boxes, UTRs as lines); the vertical line in the J-UTR represents the SG RNA start site. Recombination was initially observed when the four replicating transcripts shown with deletions in the SP-ORF (the nt number in the RUB genome of the deletion breakpoints along with restriction sites used to generate the deletions are given;deletions are indicated by dotted lines) were individually used in cotransfections with the nonreplicating transcript NR-5355-3′. Virus from nine recombinant plaques generated from DI-Stu X NR-5355-3′ cotransfections were amplified in Vero cells. The amplified stocks were used to infect Vero cells and intracellular RNA was extracted and Northern analysis was used to characterize the viral RNAs present as shown in (B). The positions of migration of Robo402, DI-Stu, and NR-5355-3′ transcripts electrophoresed in the same gel are shown in the left margin, while the genome (G), subgenome (SG), and 28S rRNA (which results in a white space) are indicated in the right margin. The RNA of five of these recombinants (2, 3, 4, 5, and 6) was sequenced across the region of overlap between the parental transcripts; the sequence of three of these recombinants was wild-type, while the other two recombinants had duplications in the 3′ end of the NS-ORF and J-UTR, as shown at the bottom (A). To test the effect of transfection reagent on recovery of recombinant virus, seven plates of Vero cells were cotransfected with DI-Stu and NR-5355-3′ transcripts using either Lipofectamine or Lipofectamine 2000. On days 4–10 posttransfection, the medium from one plate of cells was harvested and the virus present was titered by plaque assay; daily recovery of plaque-forming virus is shown in (C).
Fig. 2Recombination in the J-UTR. Genomic diagrams of pairs of replicating and nonreplicating transcripts are shown in (A) that either failed to yield recombinants (NO RECOMBINATION) or yielded recombinants (RECOMBINATION) when Lipofectamine was used as the transfection reagent. Brackets indicate nonreplicating transcripts used individually in cotransfections with a common replicating transcript with a similar result. In some cases, transcript pairs that failed to yield recombinants following Lipofectaine-mediated transfection did yield recombinants when Lipofectamine 2000 was used, as indicated by an asterisk. To determine whether the J-UTR was a recombinational hot spot, DI-Stu and NR-5355-3′ transcripts generated from constructs that had been genetically tagged with restriction sites (NsiI at the 5′ end of the J-UTR or XbaI at the 3′ end of the J-UTR) were used in cotransfections (Lipofectamine 2000) and virus recovered from recombinant plaques was sequenced across the region of overlap in the middle of the genome. As shown in (B), recombinants were recovered that had no exchange of the parental markers, exchange of parental markers, and duplications of the 3′ NS-ORF and J-UTR.
Recombination between transcripts with sequential deletions across the junction UTR
| Replicating Transcript | Nonreplicating Transcript | Lipo | Lipo2000 |
|---|---|---|---|
| DI-AB (Δ7318-9174) | NR-7318-3′ | − | − |
| DI-325 (Δ7412-9174) | NR-7318-3′ | − | − |
| RUBrep/GFP (Δ6512-9934) | NR-5355-3′ | + | + |
| NR-6263-3′ | + | + | |
| NR-6313-3′ | + | + | |
| NR-6408-3′ | − | + | |
| NR-6436-3′ | − | + | |
| DI-Stu (Δ6936-9334) | NR-5355-3′ | + | + |
| NR-6263-3′ | + | + | |
| NR-6313-3′ | + | + | |
| NR-6408-3′ | − | + | |
| NR-6436-3′ | − | + | |
| NR-6462-3′ | ND | +* | |
| NR-6467-3′ | ND | +* | |
| NR-6473-3′ | ND | +* | |
| NR-6479-3′ | ND | +* | |
| NR-6486-3′ | ND | − | |
| NR-6622-3′ | ND | − | |
| NR-6651-3′ | ND | − | |
| NR-6751-3′ | ND | − | |
| NR-6851-3′ | ND | − | |
| NR-6951-3′ | ND | − |
Vero cells were co-transfected with the indicated replicating and non-replicating transcripts; each replicating transcript contained a deletion in the SP-ORF (extent indicated) while each non-replicating transcript contained the 3′ end of the genome starting at the indicated nt (the J-UTR covers nts 6388–6512). Transfection was done either using Lipofectamine (Lipo) or Lipofectamine 2000 (Lipo2000) as the transfection reagent. +: recombination observed; −: recombination not observed; ND: not done.
With transcript pairs that produced recombinants, CPE was usually observed 8–12 days post-transfection when Lipofectamine was used and 5–8 days post-transfection when Lipofectamine 2000 was used. Co-transfections in which appearance was delayed (9–10 days post-transfection with Lipofectamine 2000) are marked with an *.
Fig. 3Recombination at the 3′ end of the genome. Genomic diagrams of pairs of replicating and nonreplicating transcripts are shown in (A) that either failed to yield recombinants (NO RECOMBINATION) or yielded recombinants (RECOMBINATION) when Lipofectamine was used as the transfection reagent. Brackets indicate both replicating and nonreplicating transcripts used individually in cotransfections with a common replicating transcript(s) with a similar result. In some cases, transcript pairs that failed to yield recombinants following Lipofectaine-mediated transfection did yield recombinants when Lipofectamine 2000 was used, as indicated by an asterisk. In (B) is shown a model based on observations reported in (A) and previous reports that initiation of negative-strand synthesis is preferential for the NS-ORF and 3′CSE in cis. When one of the transcripts has the NS-ORF and 3′CSE in cis (i), negative-strand initiation and subsequent recombination is efficient to the extent that recombination is observed when Lipofectamine is used as the transfection reagent. When the NS-ORF and 3′CSE are in trans (iv), negative-strand initiation and recombination are less efficient and recombination is only observed when Lipofectamine 2000 is employed. This model predicts that when the NS-ORF and 3′CSE are available either in cis or in trans (ii and iii), initiation of minus-strand synthesis will occur preferentially on the 3′CSE in cis with the NS-ORF. To determine from which transcript the 3′ end of the recombinant was derived in such a situation, DI-Stu and NR-5355-3′ transcripts generated from constructs with a wt 3′ end or a construct with a deletion of 5 nt from the 3′ end of the genome [these constructs maintained the poly(A) tract] were used in cotransfections (Lipofectamine 2000) and virus recovered from recombinant plaques was sequenced across the region of overlap at the 3′ end of the genome. As shown in (C), recombinants uniformly had the 3′ end derived from the replicating parental transcript (DI-Stu).
Oligonucleotides used in this study
| Number (polarity) | Sequence (5′-3′) | Properties |
|---|---|---|
| Vector Construction | ||
| 1032 (+) | GCATATGCATCTAGAATGGCTTCTACTACC | |
| 157 (−) | CGCGGATCCTACTACCAGTCCCTGCGCTGGCC | |
| 52b (+) | CGGGATCCACGCCCAC | 9174–9187 including |
| 315-1 (−) | CGTGAATTCCCACTAGCGCGGCGCTATAG | |
| 694 (+) | ACACCAATTGTTTTCGGCGGCGCCTCG | 11302–11318 (SIN) including |
| 695 (−) | CGGAATTCT20GAAATGTTAAAAACAAAATTT | |
| 326 (+) | GAGATCTTCGCCGGCATGT | 5354–5372 including |
| 105 (−) | ACGTGAATTCT20 | |
| 52 (+) | AATGCCCGAGTGGATCCA | 9163–9180 including |
| 340 (−) | CGTGAATTCT20CAGCAACAGGTGCGGGGATC | |
| 52 (+) | AATGCCCGAGTGGATCCA | 9163–9180 including |
| 315 (−) | CGTGAATTCT20CCACTAGCGCGGCGCTATAG | |
| 518 (−) | AGCTTATTTAGGGG | |
| 519 (+) | CGCGCCCCTAAATA | |
| 565 (+) | GCATGCGGCCGCTGCGGGGGCGAGAG | |
| 105 (−) | ACGTGAATTCT20 | |
| 498 (+) | TCGAAGCTT | |
| 105 (−) | ACGTGAATTCT20 | |
| 963 (+) | CCCCCATGCATATTCGGGAGAGCCCC | |
| 964 (+) | CCCCATGCATCCTCCGGAGATGACTCCG | |
| 965 (+) | CCCCATGCATCCCGGAGGAGCGGCAAGAA | |
| 966 (+) | CCCCATGCATGGGGGCTCTGCCCCGCG | |
| 967 (+) | CCCCATGCATAGGCACCCACCGAGGCCTGC | |
| 993 (+) | CCCCATGCATTGGGTACCCAACTTTTG | |
| 994 (+) | CCCCATGCATTTTTGCCATTCGGGAG | |
| 995 (+) | CCCCATGCATCCCAACTTTTGCCATTC | |
| RT-PCR 3′ end of genome | ||
| F1 (−) | CGCGAATTC(T)20CTATACAGCAACAGGTGC | |
| 52 (+) | AATGCCCGAGTGGATCCA | 9163–9180 including |
| F1 (−) | CGCGAATTC(T)20CTATACAGCAACAGGTGC | |
| 52b (+) | GGGATCCACGCCCAC | 9174–9182 including |
| 105 (−) | ACGTGAATTCT20 | |
| 52 (+) | AATGCCCGAGTGGATCCA | 9163–9180 including |
| 105 (−) | ACGTGAATTCT20 | |
| 52b (+) | GGGATCCACGCCCAC | 9174–9182 including |
| 216 (−) | CCGGTCTAGACTATACAGCAACAGGTGCGGCAATCT | |
| 52 (+) | AATGCCCGAGTGGATCCA | 9163–9180 including |
| 3′NS-ORF/J-UTR/5′SP-ORF | ||
| 325 (−) | CGGGATCCCCGGCGCGCGCGGTG | |
| 173 (+) | CCGGAATTCCGACTACAGCGCGGAGC | |
| 197 (−) | CACGAAGCTTGTGCCTCGAGGGCCTTC | |
| 177 (+) | CCGGAATTCGGTGCTTTGCCGCCGTT | |
| 550 (−) | CGCAGGCCTCGGTGGGTG | |
| 362 (+) | GCCCTTTTCGCCAGATCC | 5196–5213 |
| 1033 (−) | GTACTCTAGATTCGGGCACCCTGGGGCTC | |
| 715 (+) | GCATGCGGCCGCTTTTCGCCAGATCCC | |
| 159 (−) | CGCGGATCCTACTAAAAGACCGCGCCTTCGCC | |
| 177 (+) | CCGGAATTCGGTGCTTTGCCGCCGTT | |
Restriction sites (underlined), RNA polymerase promoters (italics) and colinear or complementary () sequences of the RUB (no designation) or SIN genome included in the oligonucleotide primer are given. (+) polarity primers are colinear with the genomic RNA sequence while (−) polarity primers are complementary.
The oligonucleotide primer pairs used to generate individual vector constructs, in order as described in the Methods section, are paired by brackets.
Oligo primers 963–967 (+) and 993–995 (+) were each used with oligo 157 (−) in vector construction.
The bracketed oligonucleotide primer pairs were used for RT-PCR to amplify regions of the genome of recombinant viruses that overlapped in the parental transcripts, the 3′ end of the genome and the regions containing the 3′ end of the NS-ORF, the J-UTR, and the 5′ endof the SP-ORF (see Fig. 1). The amplification products were then used for sequencing.